963 related articles for article (PubMed ID: 34534764)
1. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
[TBL] [Abstract][Full Text] [Related]
2. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.
Biron KE; Dickstein DL; Gopaul R; Jefferies WA
PLoS One; 2011; 6(8):e23789. PubMed ID: 21909359
[TBL] [Abstract][Full Text] [Related]
3. Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization.
Biron KE; Dickstein DL; Gopaul R; Fenninger F; Jefferies WA
Sci Rep; 2013; 3():1354. PubMed ID: 23446889
[TBL] [Abstract][Full Text] [Related]
4. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
Kuznetsova E; Schliebs R
Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
[TBL] [Abstract][Full Text] [Related]
5. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
Bell RD; Zlokovic BV
Acta Neuropathol; 2009 Jul; 118(1):103-13. PubMed ID: 19319544
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
[TBL] [Abstract][Full Text] [Related]
7. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.
Li H; Guo Q; Inoue T; Polito VA; Tabuchi K; Hammer RE; Pautler RG; Taffet GE; Zheng H
Mol Neurodegener; 2014 Aug; 9():28. PubMed ID: 25108425
[TBL] [Abstract][Full Text] [Related]
8. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
[TBL] [Abstract][Full Text] [Related]
9. Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology.
Ries M; Watts H; Mota BC; Lopez MY; Donat CK; Baxan N; Pickering JA; Chau TW; Semmler A; Gurung B; Aleksynas R; Abelleira-Hervas L; Iqbal SJ; Romero-Molina C; Hernandez-Mir G; d'Amati A; Reutelingsperger C; Goldfinger MH; Gentleman SM; Van Leuven F; Solito E; Sastre M
Brain; 2021 Jun; 144(5):1526-1541. PubMed ID: 34148071
[TBL] [Abstract][Full Text] [Related]
10. [Pathological changes induced by amyloid-β in Alzheimer's disease].
Takata K; Kitamura Y; Taniguchi T
Yakugaku Zasshi; 2011 Jan; 131(1):3-11. PubMed ID: 21212607
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular microRNA Expression Profile During Early Development of Alzheimer's Disease in a Mouse Model.
Chum PP; Hakim MA; Behringer EJ
J Alzheimers Dis; 2022; 85(1):91-113. PubMed ID: 34776451
[TBL] [Abstract][Full Text] [Related]
12. Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease.
Menet R; Bourassa P; Calon F; ElAli A
Neurochem Int; 2020 Dec; 141():104881. PubMed ID: 33068684
[TBL] [Abstract][Full Text] [Related]
13. Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
Liu CC; Yamazaki Y; Heckman MG; Martens YA; Jia L; Yamazaki A; Diehl NN; Zhao J; Zhao N; DeTure M; Davis MD; Felton LM; Qiao W; Li Y; Li H; Fu Y; Wang N; Wren M; Aikawa T; Holm ML; Oue H; Linares C; Allen M; Carrasquillo MM; Murray ME; Petersen RC; Ertekin-Taner N; Dickson DW; Kanekiyo T; Bu G
Alzheimers Dement; 2020 Oct; 16(10):1372-1383. PubMed ID: 32827351
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
15. The Neurovascular Unit Dysfunction in Alzheimer's Disease.
Soto-Rojas LO; Pacheco-Herrero M; Martínez-Gómez PA; Campa-Córdoba BB; Apátiga-Pérez R; Villegas-Rojas MM; Harrington CR; de la Cruz F; Garcés-Ramírez L; Luna-Muñoz J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670754
[TBL] [Abstract][Full Text] [Related]
16. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
[TBL] [Abstract][Full Text] [Related]
17. Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.
Mehta DC; Short JL; Hilmer SN; Nicolazzo JA
Pharm Res; 2015 Mar; 32(3):819-39. PubMed ID: 25319097
[TBL] [Abstract][Full Text] [Related]
18. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
Kurz C; Walker L; Rauchmann BS; Perneczky R
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
[TBL] [Abstract][Full Text] [Related]
19. Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer's disease, vascular dementia and mixed dementia.
Tayler H; Miners JS; Güzel Ö; MacLachlan R; Love S
Brain Pathol; 2021 Jul; 31(4):e12935. PubMed ID: 33410232
[TBL] [Abstract][Full Text] [Related]
20. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.
Yamazaki Y; Kanekiyo T
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
